The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1248 Weight Loss articles
Bank of America cuts Hims & Hers price target as the telehealth giant pivots from compounded GLP-1s to branded alternatives. Here is what this shift means for patients.
A groundbreaking study reveals that switching to an oral GLP-1 medication like orforglipron can help individuals maintain a significant portion of their weight loss achieved with injectable therapies, offering a new avenue for long-term obesity management.
Eli Lilly celebrates 150 years with a focus on AI-driven manufacturing, new GLP-1 oral therapies, and expanded neuroscience research, signaling a major shift in pharmaceutical innovation.
A comprehensive analysis of the STEP trials reveals that once-weekly semaglutide significantly benefits older adults with obesity, leading to substantial weight loss and improvements in key cardiometabolic markers. This article delves into the findings, implications, and considerations for this important demographic.
The global GLP-1 meal replacement market is experiencing explosive growth, projected to reach USD 10.9 billion by 2036. This surge is directly linked to the increasing adoption of GLP-1 medications like semaglutide and tirzepatide, alongside a growing consumer preference for convenient, nutrient-dense, and high-protein nutrition solutions designed to support weight management and reduced-appetite lifestyles.
Polycystic Ovary Syndrome (PCOS), a condition affecting millions of women, is undergoing a significant renaming to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's complex interplay with endocrine and metabolic systems, potentially improving diagnosis and treatment.
Hims & Hers reports Q1 results. See how financial growth and regulatory shifts affect patient access to semaglutide, tirzepatide, and peptide therapy.
The quest for physical perfection is driving a new trend among teen boys and young men: the use of unapproved peptides. This article delves into the motivations, the substances involved, and the significant health concerns surrounding this practice.
Mark Zuckerberg-backed AI startup Cellular Intelligence has acquired global rights to STEM-PD, an experimental Parkinson's disease cell therapy developed by Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy. This strategic move signals a new era for AI in accelerating complex therapeutic development.
